JP2016026151A5 - - Google Patents

Info

Publication number

JP2016026151A5

JP2016026151A5 JP2015154042A JP2015154042A JP2016026151A5 JP 2016026151 A5 JP2016026151 A5 JP 2016026151A5 JP 2015154042 A JP2015154042 A JP 2015154042A JP 2015154042 A JP2015154042 A JP 2015154042A JP 2016026151 A5 JP2016026151 A5 JP 2016026151A5

Authority

JP

Japan

Prior art keywords

chloro

carbonylimino

triaza

pyrazine

diamino

Prior art date

2015-08-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims 8
• 150000003839 salts Chemical class 0.000 claims 8
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 230000002265 prevention Effects 0.000 claims 2
• LCYZAZOCSZQPCI-UHFFFAOYSA-N (2-cyclohexyloxy-2-oxoethyl) 2-[4-[3-[2-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]-1,3,8-triazaspiro[4.5]dec-2-en-8-yl]-3-oxopropyl]phenoxy]acetate Chemical compound N1=C(Cl)C(N)=NC(N)=C1C(=O)NC(N1)=NCC11CCN(C(=O)CCC=2C=CC(OCC(=O)OCC(=O)OC3CCCCC3)=CC=2)CC1 LCYZAZOCSZQPCI-UHFFFAOYSA-N 0.000 claims 1
• RRBADWIMYKNTKW-UHFFFAOYSA-N (2-cyclohexyloxy-2-oxoethyl) 3-[[3-[2-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]-1,3,8-triazaspiro[4.5]dec-2-ene-8-carbonyl]phenyl]sulfonylamino]propanoate Chemical compound N1=C(Cl)C(N)=NC(N)=C1C(=O)NC(N1)=NCC11CCN(C(=O)C=2C=C(C=CC=2)S(=O)(=O)NCCC(=O)OCC(=O)OC2CCCCC2)CC1 RRBADWIMYKNTKW-UHFFFAOYSA-N 0.000 claims 1
• DFBWXKZVKQQLOM-UHFFFAOYSA-N (2-morpholin-4-yl-2-oxoethyl) 2-[4-[3-[2-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]-1,3,8-triazaspiro[4.5]dec-2-en-8-yl]-3-oxopropyl]phenoxy]acetate Chemical compound N1=C(Cl)C(N)=NC(N)=C1C(=O)\N=C/1NC2(CCN(CC2)C(=O)CCC=2C=CC(OCC(=O)OCC(=O)N3CCOCC3)=CC=2)CN\1 DFBWXKZVKQQLOM-UHFFFAOYSA-N 0.000 claims 1
• RNMRTGIATJFFQB-UHFFFAOYSA-N 2-(2-oxopiperidin-1-yl)ethyl 2-[2-chloro-4-[3-[2-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]-1,3,8-triazaspiro[4.5]dec-2-en-8-yl]-3-oxopropyl]phenoxy]acetate Chemical compound N1=C(Cl)C(N)=NC(N)=C1C(=O)\N=C/1NC2(CCN(CC2)C(=O)CCC=2C=C(Cl)C(OCC(=O)OCCN3C(CCCC3)=O)=CC=2)CN\1 RNMRTGIATJFFQB-UHFFFAOYSA-N 0.000 claims 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
• 208000025678 Ciliary Motility disease Diseases 0.000 claims 1
• 201000003883 Cystic fibrosis Diseases 0.000 claims 1
• 102000003837 Epithelial Sodium Channels Human genes 0.000 claims 1
• 108090000140 Epithelial Sodium Channels Proteins 0.000 claims 1
• MPWMUGMNVYEWIB-UHFFFAOYSA-N [2-(dipropylamino)-2-oxoethyl] 1-[[[3-[2-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]-1,3,8-triazaspiro[4.5]dec-2-ene-8-carbonyl]phenyl]sulfonylamino]methyl]cyclobutane-1-carboxylate Chemical compound C=1C=CC(C(=O)N2CCC3(NC(/NC3)=N/C(=O)C=3C(=NC(N)=C(Cl)N=3)N)CC2)=CC=1S(=O)(=O)NCC1(C(=O)OCC(=O)N(CCC)CCC)CCC1 MPWMUGMNVYEWIB-UHFFFAOYSA-N 0.000 claims 1
• QNSIIBAISJFIFD-UHFFFAOYSA-N [2-(dipropylamino)-2-oxoethyl] 2-[4-[3-[2-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]-1,3,8-triazaspiro[4.5]dec-2-en-8-yl]-3-oxopropyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OCC(=O)N(CCC)CCC)=CC=C1CCC(=O)N1CCC2(NC(/NC2)=N/C(=O)C=2C(=NC(N)=C(Cl)N=2)N)CC1 QNSIIBAISJFIFD-UHFFFAOYSA-N 0.000 claims 1
• LJZZXGNAIXMDGE-UHFFFAOYSA-N [2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl] 2-[4-[3-[2-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]-1,3,8-triazaspiro[4.5]dec-2-en-8-yl]-3-oxopropyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OCC(=O)OC(C)(C)C)=CC=C1CCC(=O)N1CCC2(NC(/NC2)=N/C(=O)C=2C(=NC(N)=C(Cl)N=2)N)CC1 LJZZXGNAIXMDGE-UHFFFAOYSA-N 0.000 claims 1
• 239000000654 additive Substances 0.000 claims 1
• 239000000969 carrier Substances 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
• 230000001404 mediated effect Effects 0.000 claims 1
• 239000003607 modifier Substances 0.000 claims 1
• 201000009266 primary ciliary dyskinesia Diseases 0.000 claims 1
• 239000012453 solvate Substances 0.000 claims 1
• 229940124597 therapeutic agent Drugs 0.000 claims 1